OXA-48-Mediated Ceftazidime-Avibactam Resistance Is Associated with Evolutionary Trade-Offs
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
OXA-48-Mediated Ceftazidime-Avibactam Resistance Is Associated with Evolutionary Trade-Offs
Authors
Keywords
-
Journal
mSphere
Volume 4, Issue 2, Pages -
Publisher
American Society for Microbiology
Online
2019-03-26
DOI
10.1128/msphere.00024-19
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A focused fragment library targeting the antibiotic resistance enzyme - Oxacillinase-48: Synthesis, structural evaluation and inhibitor design
- (2018) Sundus Akhter et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- In vivo evolution of resistant subpopulations of KPC-producing Klebsiella pneumoniae during ceftazidime/avibactam treatment
- (2018) Paolo Gaibani et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- SWISS-MODEL: homology modelling of protein structures and complexes
- (2018) Andrew Waterhouse et al. NUCLEIC ACIDS RESEARCH
- Treatment of Infections with OXA-48 producing Enterobacteriaceae
- (2018) Adam Stewart et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Conserved collateral antibiotic susceptibility networks in diverse clinical strains of Escherichia coli
- (2018) Nicole L. Podnecky et al. Nature Communications
- Estimating the number of infections caused by antibiotic-resistant Escherichia coli and Klebsiella pneumoniae in 2014: a modelling study
- (2018) Elizabeth Temkin et al. Lancet Global Health
- Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis
- (2018) Alessandro Cassini et al. LANCET INFECTIOUS DISEASES
- OXA-48-like carbapenemases producing Enterobacteriaceae in different niches
- (2017) Assia Mairi et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- Emergence of ceftazidime/avibactam non-susceptibility in an MDR Klebsiella pneumoniae isolate
- (2017) Anna Both et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Structure, activity and thermostability investigations of OXA-163, OXA-181 and OXA-245 using biochemical analysis, crystal structures and differential scanning calorimetry analysis
- (2017) Bjarte Aarmo Lund et al. Acta Crystallographica Section F-Structural Biology Communications
- Emergence of Ceftazidime-Avibactam Resistance and Restoration of Carbapenem Susceptibility in Klebsiella pneumoniae Carbapenemase-Producing K pneumoniae: A Case Report and Review of Literature
- (2017) Ryan K. Shields et al. Open Forum Infectious Diseases
- Molecular and epidemiological characterization of carbapenemase-producing Enterobacteriaceae in Norway, 2007 to 2014
- (2017) Ørjan Samuelsen et al. PLoS One
- Activity of Ceftazidime-Avibactam against Extended-Spectrum- and AmpC β-Lactamase-Producing Enterobacteriaceae Collected in the INFORM Global Surveillance Study from 2012 to 2014
- (2016) James A. Karlowsky et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Low Frequency of Ceftazidime-Avibactam Resistance among Enterobacteriaceae Isolates Carrying bla KPC Collected in U.S. Hospitals from 2012 to 2015
- (2016) Mariana Castanheira et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne bla KPC-3 Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections
- (2016) Ryan K. Shields et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections: Table 1.
- (2016) Ryan K. Shields et al. CLINICAL INFECTIOUS DISEASES
- Ceftazidime-Avibactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination for the Treatment of Resistant Gram-negative Organisms
- (2016) Roopali Sharma et al. CLINICAL THERAPEUTICS
- An in silico approach to elucidate structure based functional evolution of oxacillinase
- (2016) Arijit Pal et al. COMPUTATIONAL BIOLOGY AND CHEMISTRY
- New β-Lactamase Inhibitors in the Clinic
- (2016) Krisztina M. Papp-Wallace et al. INFECTIOUS DISEASE CLINICS OF NORTH AMERICA
- Screening and Design of Inhibitor Scaffolds for the Antibiotic Resistance Oxacillinase-48 (OXA-48) through Surface Plasmon Resonance Screening
- (2016) Bjarte Aarmo Lund et al. JOURNAL OF MEDICINAL CHEMISTRY
- One ring to rule them all: Current trends in combating bacterial resistance to the β-lactams
- (2016) Dustin T. King et al. PROTEIN SCIENCE
- Room temperature electrocompetent bacterial cells improve DNA transformation and recombineering efficiency
- (2016) Qiang Tu et al. Scientific Reports
- The global epidemiology of carbapenemase-producing Enterobacteriaceae
- (2016) David van Duin et al. Virulence
- Functional Trade-Offs in Promiscuous Enzymes Cannot Be Explained by Intrinsic Mutational Robustness of the Native Activity
- (2016) Miriam Kaltenbach et al. PLoS Genetics
- Multicopy plasmids potentiate the evolution of antibiotic resistance in bacteria
- (2016) Alvaro San Millan et al. Nature Ecology & Evolution
- Genetic and Biochemical Characterization of OXA-405, an OXA-48-Type Extended-Spectrum β-Lactamase without Significant Carbapenemase Activity
- (2015) Laurent Dortet et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- First Report of Ceftazidime-Avibactam Resistance in a KPC-3-Expressing Klebsiella pneumoniae Isolate
- (2015) Romney M. Humphries et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Potential of Tetracycline Resistance Proteins To Evolve Tigecycline Resistance
- (2015) Marius Linkevicius et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In VitroSelection of Ceftazidime-Avibactam Resistance in Enterobacteriaceae with KPC-3 Carbapenemase
- (2015) David M. Livermore et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Structural Basis for Different Substrate Profiles of Two Closely Related Class D β-Lactamases and Their Inhibition by Halogens
- (2015) Vlatko Stojanoski et al. BIOCHEMISTRY
- Temporal variation in antibiotic environments slows down resistance evolution in pathogenicPseudomonas aeruginosa
- (2015) Roderich Roemhild et al. Evolutionary Applications
- Selection and molecular characterization of ceftazidime/avibactam-resistant mutants in Pseudomonas aeruginosa strains containing derepressed AmpC
- (2015) S. D. Lahiri et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Synergistic, collaterally sensitive β-lactam combinations suppress resistance in MRSA
- (2015) Patrick R Gonzales et al. Nature Chemical Biology
- The β-Lactams Strike Back: Ceftazidime-Avibactam
- (2015) Evan J. Zasowski et al. PHARMACOTHERAPY
- Molecular Mechanism of Avibactam-Mediated β-Lactamase Inhibition
- (2015) Dustin T. King et al. ACS Infectious Diseases
- His224 Alters the R2 Drug Binding Site and Phe218 Influences the Catalytic Efficiency of the Metallo-β-Lactamase VIM-7
- (2014) Hanna-Kirsti S. Leiros et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- A high-throughput, restriction-free cloning and screening strategy based on ccdB-gene replacement
- (2014) Bjarte Lund et al. Microbial Cell Factories
- How good are my data and what is the resolution?
- (2013) Philip R. Evans et al. ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY
- Intrapatient emergence of OXA-247: a novel carbapenemase found in a patient previously infected with OXA-163-producing Klebsiella pneumoniae
- (2013) S. Gomez et al. CLINICAL MICROBIOLOGY AND INFECTION
- Ceftazidime-Avibactam: a Novel Cephalosporin/β-lactamase Inhibitor Combination
- (2013) George G. Zhanel et al. DRUGS
- Identification of Enterobacteriaceae isolates with OXA-48 and coproduction of OXA-181 and NDM-1 in Norway
- (2013) O. Samuelsen et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Kinetics of Avibactam Inhibition against Class A, C, and D β-Lactamases
- (2013) David E. Ehmann et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Use of Collateral Sensitivity Networks to Design Drug Cycling Protocols That Avoid Resistance Development
- (2013) L. Imamovic et al. Science Translational Medicine
- “Stormy waters ahead”: global emergence of carbapenemases
- (2013) Gopi Patel et al. Frontiers in Microbiology
- OXA-48-like carbapenemases: the phantom menace
- (2012) L. Poirel et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Avibactam is a covalent, reversible, non- -lactam -lactamase inhibitor
- (2012) D. E. Ehmann et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Carbapenem resistance in Enterobacteriaceae: here is the storm!
- (2012) Patrice Nordmann et al. TRENDS IN MOLECULAR MEDICINE
- Genetic Features of the Widespread Plasmid Coding for the Carbapenemase OXA-48
- (2011) Laurent Poirel et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- OXA-163, an OXA-48-Related Class D β-Lactamase with Extended Activity Toward Expanded-Spectrum Cephalosporins
- (2011) Laurent Poirel et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- BLAST Ring Image Generator (BRIG): simple prokaryote genome comparisons
- (2011) Nabil-Fareed Alikhan et al. BMC GENOMICS
- European dissemination of a single OXA-48-producing Klebsiella pneumoniae clone
- (2011) A. Potron et al. CLINICAL MICROBIOLOGY AND INFECTION
- In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae
- (2011) Z. Aktaş et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Structural and Computational Investigations of VIM-7: Insights into the Substrate Specificity of VIM Metallo-β-Lactamases
- (2011) Pardha Saradhi Borra et al. JOURNAL OF MOLECULAR BIOLOGY
- XDS
- (2010) Wolfgang Kabsch ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY
- Features and development ofCoot
- (2010) P. Emsley et al. ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY
- PHENIX: a comprehensive Python-based system for macromolecular structure solution
- (2010) Paul D. Adams et al. ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY
- Emerging carbapenemases: a global perspective
- (2010) Timothy R. Walsh INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- In Vitro Activity of NXL104 in Combination with -Lactams against Klebsiella pneumoniae Isolates Producing KPC Carbapenemases
- (2009) A. Endimiani et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Crystal Structure of the OXA-48 β-Lactamase Reveals Mechanistic Diversity among Class D Carbapenemases
- (2009) Jean-Denis Docquier et al. CHEMISTRY & BIOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More